|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5 Suppl
|
|
pubmed:dateCreated |
1998-1-14
|
|
pubmed:abstractText |
The best approach to treatment of acute myeloid leukemia (AML) in elderly patients remains controversial. Intensive chemotherapy is the treatment of choice in selected patients, but age related changes might affect the pharmacokinetics of antineoplastic agents resulting in enhanced toxicity. We report our experience in elderly patients treated with idarubicin at attenuated doses plus cytarabine and etoposide.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
13-8
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9402748-Acute Disease,
pubmed-meshheading:9402748-Aged,
pubmed-meshheading:9402748-Aged, 80 and over,
pubmed-meshheading:9402748-Antibiotics, Antineoplastic,
pubmed-meshheading:9402748-Female,
pubmed-meshheading:9402748-Humans,
pubmed-meshheading:9402748-Idarubicin,
pubmed-meshheading:9402748-Leukemia, Myeloid,
pubmed-meshheading:9402748-Male,
pubmed-meshheading:9402748-Middle Aged,
pubmed-meshheading:9402748-Remission Induction
|
|
pubmed:articleTitle |
Idarubicin in induction treatment of acute myeloid leukemia in the elderly.
|
|
pubmed:affiliation |
Divisione di Ematologia, Policlinico Careggi, Florence, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
